Table 1.

Participant characteristics

Clinical parametersN = 20 (%)
Sex  
Male 7 (35%) 
Female 13 (65%) 
Age median (range) 43.5 (19-62) 
Genotype before HSCT  
AA 3 (15%) 
AS 6 (30%) 
SS 3 (15%) 
+ 1 (5%) 
SC 2 (10%) 
Genotype SCD after HSCT (N = 5), SS 5 (100%) 
Alpha globin gene mutation  
Single mutation 10 (50%) 
No mutation detected 10 (50%) 
Hematologic data at time of enrollment (mean, SD)  
WBC (K/mcL) 6.6 ± 3.1 
RBC (M/mcL) 4.0 ± 0.9 
Hemoglobin (g/dL) 11.5 ± 2.3 
Hematocrit (%) 34.2 ± 7.5 
MCV (fL) 85.9 ± 7.6 
Platelet count (K/mcL) 308.2 ± 116.4 
ARC (K/mcL) 125.8 ± 82.2 
HbF (%) 3.2 ± 6.4 
HbA (%) 48.2 ± 32.9 
HbA2 (%) 3.2 ± 0.5 
HbS (%) 41.2 ± 24.1 
HbC (%) 43.2 ± 0 
AST (U/L) 22.6 ± 8.8 
Total bilirubin (mg/dL) 1.0 ± 0.9 
LDH (U/L) 254.2 ± 111.2 
Study duration mean number of days (range) 103 (35-147) 
Clinical parametersN = 20 (%)
Sex  
Male 7 (35%) 
Female 13 (65%) 
Age median (range) 43.5 (19-62) 
Genotype before HSCT  
AA 3 (15%) 
AS 6 (30%) 
SS 3 (15%) 
+ 1 (5%) 
SC 2 (10%) 
Genotype SCD after HSCT (N = 5), SS 5 (100%) 
Alpha globin gene mutation  
Single mutation 10 (50%) 
No mutation detected 10 (50%) 
Hematologic data at time of enrollment (mean, SD)  
WBC (K/mcL) 6.6 ± 3.1 
RBC (M/mcL) 4.0 ± 0.9 
Hemoglobin (g/dL) 11.5 ± 2.3 
Hematocrit (%) 34.2 ± 7.5 
MCV (fL) 85.9 ± 7.6 
Platelet count (K/mcL) 308.2 ± 116.4 
ARC (K/mcL) 125.8 ± 82.2 
HbF (%) 3.2 ± 6.4 
HbA (%) 48.2 ± 32.9 
HbA2 (%) 3.2 ± 0.5 
HbS (%) 41.2 ± 24.1 
HbC (%) 43.2 ± 0 
AST (U/L) 22.6 ± 8.8 
Total bilirubin (mg/dL) 1.0 ± 0.9 
LDH (U/L) 254.2 ± 111.2 
Study duration mean number of days (range) 103 (35-147) 

AST, aspartate transaminase; HbA, adult hemoglobin; HbA2, hemoglobin A2; HbC, hemoglobin C; HbS, sickle hemoglobin; MCV, mean corpuscular volume; WBC, white blood cell count.

Close Modal

or Create an Account

Close Modal
Close Modal